Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-Lactam infusion in the intensive care unit

Critical Care Nursing Quarterly

Volumn 36, Issue 4, 2013, Pages 345-355

  Guervil, David J ^a   Chau, Terence ^a  

^a MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

lactamase; Antibiotic resistance; Gram negative; Multidrugresistant

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEPHAMYCIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; QUINOLONE DERIVATIVE; SULTAMICILLIN; TIGECYCLINE; TIMENTIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG STABILITY; ESCHERICHIA COLI; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NURSE; PREVALENCE; PROTEIN EXPRESSION; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SURVIVAL; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE;

EID: 84884237147     PISSN: 08879303     EISSN: 15505111     Source Type: Journal    
DOI: 10.1097/CNQ.0b013e3182a10d2f     Document Type: Article

References (38)

1. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3): 268-281.
2. Cosgrove SE, Kaye KS, Eliopoulos GM, Caremli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162: 185-190.
3. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit setting. Ann Intern Med. 2001;134: 298-314.
4. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41: 848-854.
5. Lentino JR, Narita M, Yu VL.New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis. 2008;27(1): 3-15.
6. GiamarellouH.Multidrug-resistant gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36(suppl 2):S50-S54.
7. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillintazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3): 357-363.
8. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy. 2008;28(2): 235-249.
9. Burgess DS, Rapp RP. Bugs versus drugs: addressing the pharmacist's challenge. Am J Health Syst Pharm. 2008;65(9) (suppl 2):S4-S15.
10. Paterson DL, Bonomo RA. Extended-spectrum betalactamases: a clinical update. Clin Microbiol Rev. 2005;18(4): 657-686.
11. Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia- Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis. 2005;52(4): 323-329.
12. Sader HS, Jones RN, Gales AC, et al. Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group. Diagn Microbiol Infect Dis. 1998;32(4): 289-301.
13. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ. In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States tigecycline evaluation and surveillance trial (TEST program, 2004). Diagn Microbiol Infect Dis. 2005;52: 173-179.
14. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1): 161-182.
15. Rapp RP, Urban C. Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns. Pharmacotherapy. 2012;32(5): 399-407.
16. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis. 2009;65(4): 414-426.
17. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8(1): 71-93.
18. Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extendedspectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2): 167-174.
19. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1): 1-10.
20. Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing beta-lactam therapy. Crit Care Clin. 2011;27(1): 77-93.
21. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(suppl 1):S42-S50.
22. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 7th ed. New York: Churchill Livingstone; 2010.
23. Dow RJ, Rose WE, Fox BC, Thorpe JM, Fish JT. Retrospective study of prolonged versus intermittment infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center. Infect Dis Clin Pract. 2011;19: 413-417.
24. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2): 236-244.
25. Lorente L, Jiménez A, Martín MM, Iribarren JL, Jiménez JJ, Mora ML. Clinical cure of ventilatorassociated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents. 2009;33 (5): 464-468.
26. Gonçalves-Pereira J, Oliveira BS, Janeiro S, et al. Continuous infusion of piperacillin/tazobactam in septic critically ill patients - a multicenter propensity matched analysis. PLoS One. 2012;7(11):e49845.
27. Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006;28(2): 122-127.
28. Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg. 2000;179(6): 436-440.
29. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents. 2001;17(6): 497-504.
30. Lorente L, Jiménez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther. 2007;29(11): 2433-2439.
31. Georges B, Conil JM, Cougot P, et al. Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther. 2005;43(8): 360-369.
32. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gramnegative bacilli. Ann Pharmacother. 2006;40(2): 219-223.
33. Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2009;33(3): 290-291.
34. Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012;16(3):R113.
35. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(2): 272-282.
36. Roberts JA, Boots R, Rickard CM. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother. 2007;59(2): 285-291.
37. Lexi-Comp Online. Lexi-Drugs Online. Hudson, OH: Lexi-Comp Inc; 2013. http://online.lexi.com/. Accessed January 16, 2013.
38. Micromedex Healthcare Series. DRUGDEX System. Greenwood Village, CO: Thomson Healthcare; 2013. http://www.thomsonhc.com/. Accessed January 16, 2013.